NEW YORK (Reuters Health) – Whether clopidogrel is abruptly stopped or slowly tapered, there is no evidence of a rebound in platelet activity, German researchers report. They point…
NEW YORK (Reuters Health) – Tight glycemic control may increase the risks of mortality and cardiovascular disease, new research suggests. Moderate control, with glycosylated hemoglobin A1c (HbA1c) levels…
NEW YORK (Reuters Health) – Treating septic shock with steroids produces hyperglycemia, but patients are no better off with intensive insulin therapy than with conventional glucose control, according…
NEW YORK (Reuters Health) – High-dose atorvastatin does not protect against contrast-induced nephropathy (CIN) in patients with kidney disease, Italian researchers report. “Statins have recently been proposed for…
NEW YORK (Reuters Health) – Thiazolidinediones (TZDs) are linked to an increased risk for extremity fractures in women over age 65, findings from a large retrospective cohort study…
NEW YORK (Reuters Health) – When it comes to preventing atrial fibrillation, not all antihypertensive agents are created equal. New research suggests that angiotensin-converting enzyme (ACE) inhibitors, angiotensin…
NEW YORK (Reuters Health) – Daily treatment with diazoxide prompts a decrease in HbA1c in patients with newly diagnosed type 1 diabetes, Norwegian researchers report in the December…
NEW YORK (Reuters Health) – Women with gestational diabetes are more likely to maintain target glucose levels with glyburide than with metformin, a randomized trial has shown. The…
NEW YORK (Reuters Health) – As a mass screening tool for diabetes and pre-diabetes in China, the fasting capillary blood glucose (FCG) test performs better than the hemoglobin…
NEW YORK (Reuters Health) – The benefits of statins are variable and depend on the agent being taken, a meta-analysis has shown. Pooled data from 10 randomized trials…